To investigate the viral replication cycle and genomic heterogeneity of hepatitis C virus (HCV), we established an HCV cultivation system by using a primary hepatocyte culture from patients with chronic hepatitis C. Liver tissue was obtained by needle biopsy or surgery, then hepatocytes were isolated by collagenase digestion. After several weeks, we determined the HCV RNA titre of the cultured cells and supernatant by a competitive polymerase chain reaction (PCR) method. A significant amount of HCV RNA was observed in the cells and supernatant during cultivation. Negative-strand RNA, regarded as a marker of viral replication, could be detected by a strand-specific reverse transcription PCR method and the HCV core protein could be detected by immunofluorescence microscopy. Many HCV particles released into the supernatant were infectious. In addition, we compared the nucleotide sequences in the E2/NS1 region of pre-and post-cultivation hepatocytes for 8 weeks. At the beginning of the culture period, three major HCV types containing two subtypes were isolated. Following cultivation, the same types were isolated from the cultured hepatocytes in the same ratio as prior to cultivation. We could detect the same clones in this patient's serum, but in vivo we observed genetic variability over a 6 month interval. One clone detected throughout the 6 month period mutated extensively in the hypervariable region. These results indicated that HCV can replicate in cultured hepatocytes, and that infectious virions are released into the supernatant. This cultivation system should facilitate the study of HCV genomic heterogeneity, infection and replication.
Introduction
Hepatitis C virus (HCV) is now recognized as the principal agent of parenterally transmitted non-A, non-B hepatitis. HCV is a 9.4 kb single-stranded positivesense RNA virus encoding a large polyprotein (Choo et al., 1989; Kato et al., 1990) and has structural genes located at the 5' end of the genome preceding the nonstructural protein genes. In the codons corresponding to the N terminus of the E2/NS1 region, in particular, there are two hypervariable regions (HVR) [HVR1 (27 amino acids) and HVR2 (7 amino acids)] with marked sequence diversity (Hijikata et al., 1991 ; Weiner et al., 1991) . This region has been shown to have a high rate of mutation in HCV strains recovered from the same chronically infected patient (Kato et al., 1992; Ogata et al., 1991; Weiner et al., 1992) . HCV is also thought to have a * Author for correspondence. Fax +81 423 21 8678. e-mail yasui@to-shinkeiken.ac.jp neutralization epitope in the E2/NS1 region (Taniguchi et al., 1993; Weiner et al., 1992) . Mutations in this region may generate quasispecies variation and subsequent escape from immune surveillance.
Although our understanding of the molecular biology of HCV has progressed rapidly, little is known about its general biological characteristics because in vivo studies have been limited to chimpanzees infected with HCV. Development of efficient in vitro culture systems for HCV or readily available in vivo models are priorities for the study of HCV. HCV replication has been described from studies of liver tissue and peripheral blood mononuclear cells (PBMC) from infected patients (Willems et al., 1994; Zignego et al., 1992) . In vitro culture systems for HCV replication have been developed from human T and B cell lines (Bertolini et al., 1993; Shimizu et al., 1993) , human fetal liver cells and chimpanzee hepatocytes (Lanford et al., 1994) . A recent report showed that HCV could replicate in a human hepatoma cell line, Huh7, after transfection with HCV RNA from a putative full-length cDNA clone (Yoo et 0001-3623 © 1996 SGM T. Ito and others al., 1995) . Efficient long-term viral replication, however, has not been described in any system. Possibly HCV is stringently hepatotropic being restricted to replicate and release only in differentiated hepatocytes, which may have HCV receptors on the cell surface and specific functions that support viral growth.
In this study, we established an in vitro culture system for HCV by cultivation of human hepatocytes from patients with chronic hepatitis C. We were able to demonstrate viral replication by assaying HCV RNA both from cultured cells and from culture supernatant and by specific detection of the negative-strand viral RNA, a marker for replication (Shimizu et al., 1993; Takehara et aI., 1992; Willems et al., 1994) . HCV core protein was demonstrated in cultured hepatocytes by immunofluorescence microscopy. Furthermore, we confirmed the infectivity of the virions released into the supernatant from cultured hepatocytes by subsequent passage of HCV to uninfected human hepatocytes.
We then determined the nucleotide sequence of the E2/NS1 region from cultured hepatocytes at 8 weeks and compared the nucleotide and amino acid sequences of this HVR1 containing region in pre-and postcultivation hepatocytes. We isolated three major viral clones containing two subtypes from pre-cultivation hepatocytes. We continued to study viral sequences from this patient for 6 months and observed the changing nature of the genome of these HCV clones in contrast to the evolution of these same clones in vitro, where immune selection pressure does not exist.
Methods
Patients. We collected four liver biopsy tissues (cases 1, 2, 3 and 4) and three resected liver tissues (cases 5, 6 and 7) from seven patients (ranging in age from 34-68 years) with chronic hepatitis C who were admitted to Showa University Hospital for evaluation and treatment of chronic hepatitis C. All the cases were positive for anti-HCV antibody and HCV RNA was detected in the serum by nested RT PCR amplification of the 5' non-coding (NC) region. By histological determination, four of the liver tissues were from patients with liver cirrhosis (cases 2, 5, 6 and 7) and the others were chronic active hepatitis (cases 1, 3 and 4). The liver tissues used in this study were approved by our institutional review committee.
Primary hepatocyte cultures. Biopsy liver tissues (10 mg/specimen) were aspirated via a 14 gauge biopsy needle (True-Cut; Baxter, IL, USA). Half of each specimen was retained for histological study, while the other half was used to establish the hepatocyte culture. Three samples of resected liver were obtained from HCV RNA-positive patients with hepatocellular carcinoma. The tissue was minced in cold Ca 2+ and Mg~+-free Hanks' solution (Sigma), placed in a microfuge tube, and treated with 0.5 mu-EGTA (Sigma) for 15min on ice followed by 0.05 % collagenase I (Wako, Japan) for 30 min at 37 °C in Ca 2+ and Mge+-free Hanks' solution. The isolated cells were filtered through a 40 gm cell strainer (Falcon) and seeded in maintenance medium at a density of between 3 x 104 and 1 x 105 viable cells/cm 2 on collagen-coated tissue culture well plates. Viability was determined by trypan blue dye exclusion. Dulbecco's modified Eagle's medium (DMEM; Nissui, Japan) supplemented with 10% fetal calf serum (FCS; Sigma) and 20 ng/ml hepatocyte growth factor (HGF; Becton Dickinson Labware) was used for seeding and maintenance of cells. Cultures were incubated at 37 °C in a 5 % CO2 atmosphere and we changed culture media once every 5-7 days. We stopped the cultures after intervals of 8 weeks (cases 2 and 5), 4 weeks (case 1) and 2 weeks (cases 3, 4, 6 and 7). After cultivation, cultured hepatocytes were treated with 0-05% trypsin containing 0.53 mM-EDTA (Trypsin-EDTA; Gibco BRL) at room temperature for 10min and then harvested to stock at -70 °C for the analysis of HCV RNA by the RT-PCR method. Tissue culture supernatant was separated from cells by centrifugation. The supernatant and patients' serum were stored at -70 °C until use.
RT-PCR. HCV RNA was detected by using nested RT-PCR with primers from the 5' NC region of the HCV genome (Nakatsuji et al., 1992) . The 1 st sense primer was 5' ACTCCACCATAGATCACTCC 3' (5NC-1); the 1st antisense primer was 5' AACACTACTCGGCTAG-CAGT 3' (5NC-1R); the 2nd sense primer was 5' TTCACGCAGAAA-GCGTCTAG 3' (5NC-2); and the 2nd anti-sense primer was 5' GTTTATCCAAGAAAGGACCC 3' (5NC-2R).
RNA was extracted from harvested hepatocytes by using a nucleotide and protein extraction kit (ISOGEN; Nippon Gene, Japan). The precipitated RNA was dissolved in 50gl diethylpyrocarbonate (DEPC)-treated water and incubated for 5rain at 70 °C. Five microlitres of this solution was added to 5 jal of the reverse transcription mixture containing 100 U Moloney murine leukaemia virus reverse transcriptase (MMLV-RT; Gibco BRL), 25U RNase inhibitor (Boehringer Mannheim), 20mM-DTT, 0.5raM of each dNTP (Boehringer Mannheim), 20pmol of the 1st antisense PCR primer, an appropriate volume of reverse transcriptase buffer (5 x ) and DEPCtreated water. The cDNA synthesis was carried out at 37 °C for 40 rain.
The first PCR mixture contained 1-25 U Taq DNA polymerase (AmpliTaq; Takara, Japan), 20pmol of the 1st sense primer, an appropriate volume of PCR buffer (10 x ) and DEPC-treated water was added to the cDNA solution. The thermocycler (Techne) was programmed for 35 cycles at 94 °C for 1 min, 55 °C for 1 rain and 72 °C for 1 rain. For the second amplification, 2.5 gl were removed from the first reaction and added to a similar reaction mixture supplemented with 0.2 mM-dNTP and 20 pmol of the 2nd sense and antisense primers. The PCR was carried out as described above for the first amplification. Amplified DNA was visualized by agarose gel electrophoresis (1%) and ethidium bromide staining. The relative HCV RNA content in each well was quantified by a competitive PCR assay, in which serial dilutions of HCV with pUC19 cloned DNA inserted in its 5' NC region (with a 15 base pair deletion at the middle portion) served as a competitor.
To quantify the HCV RNA in a sample, we prepared four tubes containing four couples of serial diluted samples and internal control (tube 1, undiluted samples only; tube 2; 10-fold diluted samples with 101 copies of internal control cDNA; tube 3; 100-fold diluted samples with 102 copies of internal control; tube 4; 1000-fold diluted samples with 103 copies of internal control) and determined the HCV RNA content of samples judging from the comparison of two cDNA signals. This method enabled us to determine the HCV RNA content within a range of 101-107 copies of HCV RNA. We assayed one part of the total RNA of samples and calculated the total HCV RNA content per well. This internal control was kindly provided by M. Kohara (Tokyo Metropolitan Institute of Medical Science, Japan) and K. Yamaguchi (Tonen Corporation, Japan).
Negative-strand HCV RNA in cultured hepatocytes (strand-specific R T-PCR) . For detection of negative-sense HCV RNA strands, we used a tagged RT-PCR method that specifically detected the negative-strand HCV RNA (Lanford et al., 1994) . For detection of the negative-strand RNA, cDNA synthesis was performed with an oligonucleotide primer containing a tag sequence (in bold) unrelated to HCV at its 5' end and the outer sense primer 5NC-I, (5' TCATGGTGGCGAATAAACTC-CACCATAGATCACTCC Y, Tag-5NC-1) and was performed as described above. The cDNA synthesis was stopped by heating at 99 °C for 1 h. The samples were treated with 50 gg/ml RNaseA (Boehringer Mannheim) at 37 °C for 30 min in order to digest the RNA and thereby avoid possible reverse transcription and subsequent amplification of positive-sense RNA strands by Taq polymerase (Willems et aL, 1994) .
As a negative control, we performed cDNA synthesis without primer using RNA extracted from liver tissue homogenates containing high quantities of HCV to detect the non-specific reaction caused by selfpriming of positive-strand RNA (Lanford et al., 1994) . The 1st PCR was carried out as described using the sense primer of the tag sequence alone (5' TCATGGTGGCGAATAA 3', Tag) and the 5NC-IR primer, then the 2nd PCR was performed using the Tag and the 5NC-2R primers.
Immunofluorescence microscopy. HCV-infected hepatocytes obtained from a non-cancerous portion of resected liver (case 7) were grown for 14 days on collagen-coated chamber slides (Lab-Tek; Nunc). Following removal of the culture medium, the cells were briefly dipped once or twice into PBS. The chamber slides then were fixed in acetone for 5 min at -2 0°C and air dried. Indirect immunofluorescence antibody analysis was carried out with an anti-HCV core monoclonal antibody; this monoclonal antibody was obtained from a mouse that had been immunized with highly purified core protein, which was isolated from Escherichia coli that expressed the HCV core gene. The secondary antibody was a fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG (Cappel). We prepared COS7 cells transfected with cDNA corresponding to the HCV core region as a positive control. The cDNA clones were expressed in COS7 cells by using an SR~ promoter (Takebe et al., 1988) . COS7 cells were transfected with the plasmid DNA in the presence of lipofectin (Gibco BRL).
Sequencing of cloned cDNA from PCR products of the E2/NS1
region. We compared the nucleotide sequences of the HCV E2/NS1 region RNAs from cultured and uncultured hepatocytes as a means of monitoring the HCV genome for mutations during culture. We amplified 491 base pairs of the E1 and E2/NS1 region containing the HVRs by the nested PCR method [lst sense primer 5' CGCATGGCTTGGGATATGAT 3' (HVR-1); 1st antisense primer 5' TCGGTCGTCCCCACTACAAC 3' (HVR-1R); 2nd sense primer 5' GGGGCCCACTGGGGTGTCCT 3' (HVR-2); 2nd antisense primer 5' GGGCTCGGAGTGAAGCAATA 3' (HVR-2R)] after synthesizing cDNA with the 1 st antisense primer and cloned the PCR products into the M 13 vector (M 13mp 19; Wako, Japan). Nucleotide sequences of the clones containing HCV cDNA were determined by the dideoxynucleotide chain-termination method using T7 DNA polymerase with sequencing primers (AutoRead Sequencing Kit; Pharmacia). Over a 6 month period, we compared the sequences of serum HCV RNA and HCV RNA from in vitro culture, which lacked the immune pressure of natural selection.
Results

Sensitivity o f this competitive P C R assay
To confirm the sensitivity of our competitive PCR assay, we quantified a known concentration of a synthetic HCV RNA both by using a competitive PCR system and by using a competitive RT PCR system established by other groups (Kaneko et al., 1992; Hagiwara et al., 1993) . In the competitive RT-PCR assay, we used serially diluted HCV RNA mutated in its 5' NC region for an internal control. The synthetic HCV RNA and the internal control were kindly provided by M. Seki (Mitsubishi Chemical, Japan) and synthesized by in vitro transcription of the T7-based plasmids pT7NI-19 linearized with BamHI, which contained nucleotides 1-2006 of the HCV genome and its mutant with a SalI site inserted in its 5' NC region (Seki & Honda, 1995) . We quantified 106 copies of the synthetic RNA as l0 G copies using both systems and we quantified 102 copies of the RNA as 103 copies by our system and as 102 copies by the competitive RT-PCR (Fig. 1) . The other titres of the synthetic RNA were almost the same titres using by these two systems.
We added 106 copies of synthetic RNA to HCVnegative cultured hepatocytes and to culture media alone for 4 weeks and quantified the HCV RNA titre by using our system. The titre of HCV RNA extracted from cultured cells was 102 copies and from culture medium was 10 ~ copies. These results indicated that naked single-T. Ito and others in culture media (case 6) was assayed by competitive PCR at 1, 12, 24, 48 h and 5 days (120 h) after the full medium exchange on day 7. For each sample time, one-fifth of the culture media was exchanged with fresh medium and its HCV RNA content was quantified. The HCV RNA titre was less than 101 copies after 1 h, l0 s copies after 12 h, 103 copies after 24 h and 104 copies after both 48 h and 5 days. (d) HCV RNA titre in culture medium (case 6) during cultivation. The HCV RNA titres (O) represent the total amount of HCV RNA per microtitre well culture.
stranded RNA was extensively digested by RNase in the culture medium and especially in cultured cells during treatments. So our system may underestimate the amount of RNA in the sample.
Replication of HCV in cultured hepatoeytes
In each hepatocyte culture system from cases 1-5, HCV RNA was detected both in cells and supernatant throughout the culture period, as measured by competitive PCR (Fig. 2a, b) . The medium of each hepatocyte culture was changed at 5 to 7 day intervals. In three cases (cases 1, 3 and 4) obtained from patients with chronic hepatitis, the PCR value remained stationary both in the cells and in the supernatant for 2 to 4 weeks at a time. In two cases (case 2 and 5) from patients with liver cirrhosis, the level of HCV RNA in the cells decreased for 4 weeks, but HCV was continuously released at consistently high titre for 8 weeks. In addition, we assayed the titre of the HCV RNA in culture medium during the shorter interval. We also cultured hepatocytes obtained from an HCV-infected patient (case 6) with liver cirrhosis as described and totally changed the culture medium on day 7. After that the medium was sampled by withdrawing one-fifth of the culture medium and replacing the same amount of fresh medium to the wells. Then we quantified its HCV RNA content at 1, 12, 24, 48 and 120 h after the complete medium change. Fig.  2(c, at) show that released HCV increased until 48 h after the medium change on day 7 after which it reached a plateau level. HCV has a single-strand RNA genome with positive polarity. Viral replication is indicated by detection of negative-strand RNA., Therefore, we determined the negative-strand RNA in cultured hepatocytes for 4 weeks (cases 1, 2 and 5) during which the HCV RNA level in the cells and in the culture supernatant remained high. Following 28 days of culture, the negative-strand RNA was observed in cultured hepatocytes by ethidium bromide staining of RT-PCR products (Fig. 3) . No HCV RNA was observed in the control HCV RNA extracted from HCV-infected liver tissues as determined by cDNA synthesis in the absence of primers.
When examined by immunofluorescence microscopy for HCV core protein by using an anti-HCV core monoclonal antibody, a granular staining pattern was observed in the cytoplasm of both the cultured hepatocytes at 14 days (Fig. 4b ) and the positive control (Fig.  4a) . The anti-HCV core monoclonal antibody used for this test could react with the authentic virion core protein, because the antibody could capture HCV virion cores containing RNA by the capture PCR method (Shindo et al., 1994; J. Zuo, K. Yasui et al., unpublished data) .
Infectivity of the released H C V in the culture supernatant
To determine the infectivity of HCV particles released into the culture supernatant, we inoculated the culture supernatant in an HCV-negative hepatocyte culture and assayed for negative-strand HCV RNA. We harvested culture supernatant with 3x105 copies of HCV RNA/100 gl from a primary hepatocyte culture (case 5). HCV-negative hepatocytes were taken from two patients (cases 8 and 9) with metastatic liver tumours who did not have anti-HCV serum antibodies or HCV RNA. Fot- lowing isolation, hepatocytes were seeded at a concentration of 5 x 104 cells/well in 200 gl of maintenance medium supplemented with the culture supernatant containing HCV and incubated over night at 37 °C. Following incubation, the medium was replaced with normal medium. On days 3 and 7 after initiating the culture, we replaced the medium and looked for the presence of negative-strand HCV RNA by the strandspecific R T P C R as described. Fig. 5(a) shows that positive-strand RNA was detected in cultured hepatocytes on days 3 and 7; negative-strand RNA was not detected on day 3, but was seen on day 7 in each case. The titre of positive-strand RNA (case 8) increased from 102 copies/well on day 3 to 103 copies/well on day 7.
HCV RNA in the culture media was detected on day 7 (case 9) and its PCR titre was 5 x 102 copies/well. When we inoculated with HCV in culture medium to the another HCV-negative hepatocyte culture as previously described, the intracellular HCV R N A was also detected after inoculation. The HCV-negative hepatocyte culture (case 8) was infected with HCV released from the H C V hepatocyte culture. After infection, we determined whether or not a correlation existed between HCV-replicating cells and albumin-producing cells. Fourteen days after the infection, we examined a double staining of indirect immunofluorescent antibody using anti-HCV core mouse monoclonal antibodies and an anti-human albumin rabbit polyclonal antibody (Cappel) mixture. An FITC-conjugated anti-mouse I g G (Cappel) and a Texas red-conjugated anti-rabbit I g G (Cappel) mixture were used as second antibody. The HCV core protein was detected mainly in the cultured hepatocytes which expressed human albumin (Fig. 5b) .
T. Ito and others (a)
To analyse the nature of the released H C V particles, we layered 100 gl of hepatocyte culture supernatant (case 5; day 7) onto a 10 to 40 % continuous sodium iotalamate (Angio Conray; Daiichi-seiyaku, Japan) gradient in 20 mM-Tris-HC1 p H 8"0 and 0" 15 M-NaC1. Subsequently we fractionated the gradient after ultracentrifugation at 121000 g in a Beckman SW41 Ti rotor for 16 h at 4 °C. HCV R N A titres in each fraction were assayed by competitive PCR. High H C V R N A titres were found at 1.16 to 1'20 g/ml with the HCV R N A peak was in 1.18 g/ml.
In addition, infectious culture medium was inactivated by ultraviolet (UV) irradiation. The HCV R N A content of HCV-negative hepatocytes inoculated with the infectious culture media was 10 a copies/well without inactivation and 101 copies/well with the UV inactivation 7 days after inoculation. For the detection of positive-sense RNA, the 5NC-1R primer was used for cDNA synthesis (lanes 1 and 2) and for the detection of negative RNA strands, the Tag-5NC-1 primer was used (lanes 3 and 4). On days 3 (lanes 1 and 3) and 7 (lanes 2 and 4) after initiating the culture, both positive and negative RNA strands were analysed in cultured hepatocytes. (b) Double staining of cultured hepatocytes (case 8) 14
H C V quasispecies in infected patients: comparison of genomic fluctuation between in vitro and in vivo viral life cycle
We found three major types containing two subtypes of H C V clones classified by the 1150-1419 nucleotide dendrogram in the E2/NS1 region in the original hepatocytes and in serum from the same patient (Fig.  6 a) . Likewise, the HCV clones were classified according to the deduced amino acid sequences in this region. Type A, B and C clones had different sequences through this region with nucleotide identities of 88 to 94 % (Fig. 6b) . Type B1 and B2 clones had the same amino acid sequence in the n o n -H V R (410-474), but HVR1 sequences were different. Type B2 clone was not found in days after the infection using anti-human albumin polyclonal antibodies (i) and a mixture of anti-HCV core monoclonal antibodies (ii). Scale bar represents 20 ~tm.
In vitro culture of HCV in human hepatocytes
1049 cells on day 0, but could be detected both in serum on day 0 and in cells on day 56. Type D clone was found neither in cells nor in serum on day 0, but was detected in serum following 1 month and the nucleotide identity of 89 % between the D and B2 clone was the highest of all. This patient was not treated with interferon. The alanine aminotransferase (ALT) concentration varied from 50 to 100 IU/1 and HCV RNA was stable at 10 s copies/ml during the 6 month interval. We analysed fluctuations in the proportion of these clones over 6 months and compared these changes with the cultured hepatocytes pre-and post-cultivation.
HCV clone population variations are shown in Fig 7. Two major (types A and B1) and one minor quasispecies (type C) were detected before initiating the culture. The two major quasispecies were also detected in the same population ratio following a 56 day culture. In the patient's serum, one major species (type A) and two other quasispecies (types B1 and B2) were detected on day 0. But 1 month later, the type A clone h~d decreased while the B 1 clone increased and became the major clone, becoming as much as 70 % of the population. A type D clone was detected de novo in serum after the first month. Six months after beginning the culture, the type A and T. Ito and others B2 clones disappeared completely. The type C clone, which was detected in hepatocytes on day 0 in only as many as 5 % of the total clones, eventually became a major clone in the serum.
Comparison between in vitro and in vivo H C V genomic mutations in the E 2 / N S 1 region
In patient's serum (case 2), we consistently detected one clone (type B1) throughout the 6 month interval. We determined the frequency of genomic mutations in the E2/NS1 region containing HVR1 (Fig. 6a) by sequencing of this clone. Genomic mutations were observed mainly in HVR1. On day 0, we detected the B1 clone without variation both in cells and in serum.
In vitro, in the cultured hepatocytes, nucleotide changes in HVR1 occurred in 4 of 11 clones at a frequency of 1-4%, and resulted in few amino acid replacements (Fig. 8 a, b) . In the infected patient, on the other hand, even by one month nucleotide mutations occurred in 5 of 9 clones with a frequency of 1 to 4 %. By 6 months 5 of 6 clones showed a mutation frequency of 3 to 18% in association with many amino acid replacements (Fig. 8c, d) . Clearly, in vivo amino acid mutations accumulated in the HVR1 region over the 6 month interval. Furthermore, we analysed the A clone in the same manner as the B 1 clone. In cells on day 0, 6 of 8 clones had the same sequences defined as type A and another two clones had two nucleotide changes in the HVR1. In serum on day 0, 8 of 10 clones had the same sequences as type A and another two clones had one nucleotide change. In the cultured hepatocytes on day 56, 6 of 8 clones were the same as type A clones and the others had one nucleotide change in the HVR1. In the infected patient, we could detect only one clone of type A after 1 month and found no clones of type A after 6 months. In genome of the clone detected after 1 month, one nucleotide change was observed with an amino acid replacement.
In the culture supernatant on day 7, we detected the same A1 clone as in cells on day 0. At this time 10 of 12 clones had the same sequence as the original clone and 2 of 12 clones had one nucleotide change in the HVR1.
Discussion
HCV preferentially infects and replicates in human or chimpanzee hepatocytes. Differentiated hepatocytes have specialized characteristics such as production of specific proteins and lipoproteins. A human T cell line can support HCV replication in vitro for several weeks (Shimizu et al., 1993 (Shimizu et al., , 1994a as can a primary chimpanzee hepatocyte culture system (Lanford et al., 1994) . However, HCV culture in human hepatocytes in vitro has not been reported. Because of the need for a human hepatocyte culture system in understanding the molecular biology of HCV infection and replication and in unravelling how genetic variants evolve in hepatocytes, we developed an in vitro human hepatocyte culture and demonstrated that it could support HCV replication.
The present study revealed that: (i) HCV replicated in vitro in this culture system. A high titre of HCV particles were released from infected hepatocytes into the culture medium and were infectious to other hepatocytes and (ii) most HCV clones remained genetically stable in this in vitro system as compared with natural infection in the whole organism. To demonstrate viral replication in in vitro culture systems, to assay not only for positive-sense HCV RNA but also for negative-sense RNA is generally recommended Lanford et al., 1994; Shimizu et al., 1993) . In our culture system, both positive-and negative-sense RNA strands were detected in cultured hepatocytes and the titre of HCV RNA remained static during the 4 week culture interval. On harvesting cultured hepatocytes, we suspended the cells by trypsin treatment. Free HCV particles on the surface of hepatocytes can be removed by this treatment. We assumed, therefore, that hardly any contamination by extracellular HCV occurred in our system. Furthermore, HCV released into the culture medium was detected throughout the culture period and the viral RNA titre rapidly increased to a certain extent after the medium exchange. These results showed that HCV replicated in cultured hepatocytes and that virions were constantly released into the supernatant. The released virions were infectious to human hepatocytes, so virions must have been structurally complete to be able to interact with the viral receptor on the hepatocyte surface. In infected cells, HCV is thought to synthesize negative RNA strands during the initial step of replication after uncoating. Fig.  5 (a) showed that HCV started to replicate in cultured hepatocytes directly after infection. UV treatment partially destroyed viral infectivity of uninfected hepatocytes.
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The buoyant density of flavivirus particles is 1.18 1.20g/ml in sucrose (Brinton, 1986) and HCV virions in patients' sera were recently reported to exist at a density of 1.14-1.16 g/ml when using immunoelectron microscopy to titre the virus in the gradient fractions (Kaito et at., 1994) . Our data indicated that the buoyant density of HCV virions released from hepatocytes into supernatant ranges from 1.16 to 1-20 g/ml, the peak fraction was at 1'18 g/ml. These data were in the same range as the previous reports and show that the density of released HCV particles from hepatocytes is the same as that of other flaviviruses. Some papers have reported that HCV in patients' sera sedimented in lighter fractions (Hijikata et al., 1993) and bound to lipoproteins. The density of HCV particles in serum was consistent with the density of virions released from infected hepatocytes and intracellular virions from immunologically disrupted hepatocytes. The latter virions may be complexed with other molecules such as lipoprotein or immature particles like those observed in flavivirus-infected cells. We analysed the centrifugation profile of intracellular HCV. Homogenized liver tissue from patient case 5 was layered on the same gradient described previously and centrifuged. We detected HCV from liver tissue in the light fraction (data not shown).
Two cases in which viral titres decreased after 4 week intervals were obtained from patients with liver cirrhosis (LC), however chronic active hepatitis (CAH) cases showed a continuous level of HCV RNA titre during infection. We isolated fewer hepatocytes from LC liver specimens than from CAH hepatocytes suggesting that some infected cells in culture might be injured by trypsinization when harvested. The stability of viral titres in these culture supernatants from day 7 to day 28 showed that HCV replicated in the surviving cells for the duration. Negative-strand RNA was also detected in these cells on day 28.
Detection of the HCV core protein in cultured hepatocytes by immunofluorescence microscopy indicated that HCV RNA was translated and HCV proteins were produced in cultured hepatocytes. The frequency of core protein-positive cells in the population was less than 10 % (data not shown). The cultured hepatocytes, which were most similar to native liver, appeared to be more susceptible to HCV infection based on the results of the double staining experiment with anti-HCV core and antihuman albumin. But positive staining of HCV core protein was observed in some hepatocytes whose albumin expression was negative, so further study is required to analyse the correlation between HCV core protein expression and the cellular protein synthesis of host cells.
HCV is thought to constitute a new genus of the Flaviviridae family judging from the organization of the genome and the amino acid sequence of the polyprotein (Kato et al., 1990; Okamoto et al., 1992) . Flaviviruses have some epitopes for viral neutralization in the envelope (E) region (Kimura-Kuroda & Yasui, 1988; Lobigs et al., 1987) . Anti-E antibodies in patient serum may play an important role in viral neutralization, because HCV also has E spike proteins. Chimpanzees immunized with both putative envelope glycoproteins, E 1 and E2 (copurified from transfected mammalian cells) were protected against an infectious challenge with HCV (Choo et al., 1994) . The N terminus of the E2/NS1 region contains two hypervariable regions (HVR) with marked sequence diversity (Hijikata et al., 1991; Weiner et al., 1991) . These regions have a high rate of mutation over time in HCV strains recovered from the same chronically infected patient (Kato et al., 1992; Ogata et al., 1991 ; Weiner et al., 1992) . This domain is thought to be a target for the human immune response (Taniguchi et al., 1993; Weiner et al., 1992) . If the mutation rate in key epitopes outpaces the rate of host immune response against those same epitopes, then the virus may be able to persist in the host.
HCV populations in vivo consist of quasispecies that differ within the HVR and these populations evolve differently in each patient during the natural history of persistent infection (Enomoto et al., 1994) . In the present study, the patient in case 2 had HCV quasispecies clones both in hepatocytes and in serum before initiating hepatocyte culture. We therefore monitored the quasispecies population both in vitro without immune pressure and in vivo. In the in vitro culture system, no variations within the population were observed between pre-and post-cultivation, but dynamic changes were observed in the patient's serum. In addition, genomic mutation in the HVR1 was observed in one serum clone, type B1, which was always present during the 6 month interval both in the in vitro culture system and in vivo. Mutations in the serum clone accumulated predominantly in the HVR1 and the number of the original clones without mutations decreased over the 6 month interval. On the other hand, in vitro, nucleotide mutations accompanied by amino acid replacements were observed in a few clones, but most clones had no mutation after 2 months in culture. The same result was observed with type A clones.
From these results, it appears that genetic evolution of HCV quasispecies may be influenced by host immune pressure, and that replication of each viral clone is reasonably stable in the absence of immune pressure. As in all RNA viruses, spontaneous mutations in the HCV genome due to misreading during replication will occur at a background frequency. Therefore, HCV is expected to mutate even in vitro. Under immune pressure, in natural infection, mutants in the HVR can escape from the host immune response and gain a selective advantage until specific antibodies or a cell-mediated immune response to the mutant protein appear. Both quasispecies variation and the development of escape mutants may enable HCV to infect persistently.
The mechanisms of HCV infection, replication, assembly, and neutralization can now be studied in detail in vitro. This system should also prove useful for investigating the genesis of spontaneous genomic heterogeneity in vitro without immune pressure, which can be compared and contrasted with natural infection.
